Literature DB >> 26833957

Design and analysis of clinical trials in the presence of delayed treatment effect.

Tony Sit1, Mengling Liu2, Michael Shnaidman3, Zhiliang Ying4.   

Abstract

In clinical trials with survival endpoint, it is common to observe an overlap between two Kaplan-Meier curves of treatment and control groups during the early stage of the trials, indicating a potential delayed treatment effect. Formulas have been derived for the asymptotic power of the log-rank test in the presence of delayed treatment effect and its accompanying sample size calculation. In this paper, we first reformulate the alternative hypothesis with the delayed treatment effect in a rescaled time domain, which can yield a simplified sample size formula for the log-rank test in this context. We further propose an intersection-union test to examine the efficacy of treatment with delayed effect and show it to be more powerful than the log-rank test. Simulation studies are conducted to demonstrate the proposed methods.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  lagged treatment effect; log-rank test; power calculation

Mesh:

Year:  2016        PMID: 26833957      PMCID: PMC4828286          DOI: 10.1002/sim.6889

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

2.  Design and analysis of non-inferiority mortality trials in oncology.

Authors:  Mark Rothmann; Ning Li; Gang Chen; George Y H Chi; Robert Temple; Hsiao-Hui Tsou
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

3.  Two-stage adaptive design for clinical trials with survival data.

Authors:  Gang Li; Weichung J Shih; Yining Wang
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

4.  Sample sizes based on the log-rank statistic in complex clinical trials.

Authors:  E Lakatos
Journal:  Biometrics       Date:  1988-03       Impact factor: 2.571

5.  Sample izes for medical trials with special reference to long-term therapy.

Authors:  M Halperin; E Rogot; J Gurian; F Ederer
Journal:  J Chronic Dis       Date:  1968-01

6.  Power and sample size calculation for log-rank test with a time lag in treatment effect.

Authors:  Daowen Zhang; Hui Quan
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

  6 in total
  4 in total

1.  Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

Authors:  Zhenzhen Xu; Bin Zhu; Yongsoek Park
Journal:  Stat Med       Date:  2020-09-17       Impact factor: 2.497

2.  Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.

Authors:  Kim Jachno; Stephane Heritier; Rory Wolfe
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

3.  Examining evidence of time-dependent treatment effects: an illustration using regression methods.

Authors:  Kim M Jachno; Stephane Heritier; Robyn L Woods; Suzanne Mahady; Andrew Chan; Andrew Tonkin; Anne Murray; John J McNeil; Rory Wolfe
Journal:  Trials       Date:  2022-10-06       Impact factor: 2.728

4.  Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.

Authors:  Zhenzhen Xu; Yongsoek Park; Ke Liu; Bin Zhu
Journal:  J Hematol Oncol       Date:  2020-03-14       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.